一項涉及多達 270 名嚴重 COVID-19 肺病住院患者的全球第 2/3 期研究，以及一項涉及多達 40 名患者的美國第 2 期研究，目前正在使用 opaganib。它是一種新型、口服鞘氨醇激酶-2 (SK2) 選擇性抑制劑，具有雙重抗炎和抗病毒特性Opaganib 已從賓夕法尼亞的 COVID-19 疫苗、治療和治療計劃中獲得資助，該計劃支持前景明朗的新型 COVID-19 療法快速發展以色列特拉維夫和紐約市拉里, Sept. 08, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd.（納斯達克：RDHL）（「RedHill」或「公司」）是一家專業生物製藥公司，今天宣佈選擇 opaganib1，一種專利、一流、口服鞘氨醇激酶-2 (SK2) 選擇性抑制劑，現正評估其用於治療嚴重 COVID-19 肺炎的藥效，並從賓夕法尼亞州的 COVID-19 疫苗、治療及療法 (CV-VTT) 計劃中獲得 30 萬美元的資助，而該計劃旨在支持新型 COVID-19 療法快速發展而設計。此撥款已授予 RedHill 的合作夥伴 Apogee Biotechnology Corporation，而 RedHill 從中獲得 opaganib 授權，並將進行獲得資助的研究。RedHill 高級副總裁 Reza Fathi 博士說：「我們很高興賓夕法尼亞州認同我們第 2/3 階段候選藥物 opaganib 作為 COVID-19 患者急需治療選擇的潛力。 此項資助將有助於加速和擴展 opaganib 的發展，從而實現我們透過產生可靠數據潛在支援 COVID-19 緊急使用應用程式的目標。」來自賓夕法尼亞州的 CV-VTT 資助將涵蓋關鍵的臨床前機制研究，進一步驗證 opaganib 在抑制與 COVID-19 相關急性呼吸窘迫綜合徵 (ARDS) 相關的程度及/或持續時間的潛在作用。迄今為止，全球第 2/3 期評估 opaganib...

关于具有抗炎和抗病毒双重特性的新型口服鞘氨醇激酶-2（SK2）选择性抑制剂opaganib，目前正在进行270名重症新冠肺炎住院患者全球2/3期研究和40名患者美国2期研究Opaganib已入选获得宾夕法尼亚州新冠肺炎疫苗、药物和疗法计划的拨款，该计划旨在为有发展前景的新冠肺炎新型疗法的快速推进提供支持以色列特拉维夫和北卡罗来纳州罗利, Sept. 08, 2020 (GLOBE NEWSWIRE) — 特种生物制药公司RedHill Biopharma Ltd.（Nasdaq：RDHL）（以下称“RedHill”或“该公司”）今天宣布，正在接受重症新冠肺炎疗效评估的同类首创专有口服鞘氨醇激酶-2（SK2）选择性抑制剂opaganib已获选1，将接受宾夕法尼亚州新冠肺炎疫苗、药物和疗法（CV-VTT）计划提供的30万美元拨款。该计划旨在为新冠肺炎创新疗法的快速推进提供支持。该项拨款授予了RedHill的合作伙伴Apogee Biotechnology Corporation。RedHill获得这家公司关于opaganib的授权，将在拨款支持下进行这项研究。“我们很高兴宾夕法尼亚州认识到我们2/3期候选药物opaganib作为新冠肺炎患者亟需治疗选项的潜在开发前景，” RedHill研发高级副总裁Reza Fathi博士表示。 “这笔拨款将有助于加速和扩大opaganib的开发以力争实现我们的目标：生成强大数据包以用于对新冠肺炎紧急用药申请提供潜在支持。”宾夕法尼亚州的CV-VTT拨款将用于关键的临床前机理性研究，以进一步阐明opaganib在抑制新冠肺炎相关急性呼吸窘迫综合征（ARDS）的程度和/或持续时间方面的潜在作用。到目前为止，对opaganib新冠肺炎疗效进行评估的全球2/3期研究已在英国、意大利、俄罗斯和墨西哥获得批准，患者招募正在进行并计划进一步扩大研究规模。这是一项多中心、随机、双盲、平行、安慰剂对照的2/3期研究（NCT04467840），计划招募270名需要住院治疗和辅助供氧的新冠肺炎重症患者参与试验。与全球2/3期研究同时进行的美国opaganib二期临床研究的患者招募已完成超过50%，整个招募工作将在未来几周完成。一个预先安排的独立安全监测委员会最近建议，这项研究应继续按原计划进行。下一次拟定安排的安全审核将在24名患者完成7天治疗后进行。这项随机、双盲的安慰剂对照研究（NCT04414618）并非以统计显著性为目标，旨在招募40名需要住院治疗和辅助吸氧的新冠肺炎重症患者参与试验。关于opaganib（ABC294640，Yeliva®）opaganib是一种新的化学体，一种专有的首创性口服鞘氨醇激酶-2（SK2）选择性抑制剂，具有抗肿瘤、抗炎和抗病毒活性，针对多种肿瘤、病毒、炎症和肠道适应症。通过抑制SK2，opaganib可影响与癌细胞生长、病毒复制和病理炎症相关的多种细胞路径。opaganib最初由美国Apogee...

BOSTON, Sept. 07, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that topline results from the PEDFIC 1 Phase 3 clinical trial evaluating the efficacy and safety of lead candidate odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC) will be announced September 8, 2020. Company management will host a conference call and live audio webcast at 8:30 a.m. EDT to review the results.To access the live conference call and webcast tomorrow, September 8, 2020, at 8:30 a.m. EDT, please dial 877-407-0792 (domestic) or 201-689-8263 (international) and provide the access code 13709929. The live audio webcast of the presentation will be accessible from the Media & Investors page of Albireo’s...

TORONTO, Sept. 07, 2020 (GLOBE NEWSWIRE) — Melior Resources Inc. (TSXV: “MLR”) (“Melior” or the “Company”) today has entered into an amended demand promissory note (the “Amended Promissory Note”) with Pala Investments Limited (“Pala”), a shareholder of Melior.On November 20, 2019, the Company entered the promissory note (“Promissory Note”) with Pala, totaling US$105,550 and maturing on March 31, 2020.  The maturity was subsequently amended to October 31, 2020.  Further details of the terms of the Promissory Note can be found in the press release of November 20, 2019.Today, Melior entered into an Amended Promissory Note, increasing the amount of the Promissory Note by US$50,000 to a total of US$155,550 and extending the maturity of the loan from October 31, 2020 to December 31, 2020.  All other terms of the Amended Promissory Note...

GAUMONTInformations relatives au nombre total de droits de vote et d’actions du capital socialprévues par l’article L. 233-8-II du code de commerceet l’article 223-16 du règlement général de l’Autorité des marchés financiersLe 7 septembre 2020Gaumont est une société cotée sur Euronext Paris – Eurolist Compartiment B – Code ISIN FR0000034894 – www.gaumont.frPièce jointeversion pdf

The operations of Icelandair Group continued to be heavily impacted by the COVID-19 pandemic in August. Although some travel restrictions had been lifted from 15 June and Icelandair had somewhat expanded its flight schedule again, new travel restrictions were implemented on 19 August affecting demand to and from Iceland for the remainder of the month. The Company’s freight services continued to decrease much less due to the situation than the capacity reduction of the Icelandair route network.The total number of Icelandair’s passengers in August were around 67,100, decreasing by 88% from August 2019. The number of passengers to Iceland were around 52,600 and from Iceland almost 13,200. Number of via passengers was insignificant, reduced by 99%. The load factor on Icelandair’s flights was 67.8% compared to 83.2% in August 2019. The total...

press releaseKLÉPIERRE PUBLISHESITS FIRST-HALF 2020 FINANCIAL REPORTParis – September 7, 2020Klépierre announced the public release and the filing of its first-half 2020 financial report with the Autorité des marchés financiers (“AMF”) on September 7, 2020.It may be read and downloaded from the Klépierre website, www.klepierre.com, under the “Finance” section. 

COMMUNIQUÉMISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2020Paris – le 7 septembre 2020Klépierre a mis à la disposition du public et déposé son rapport financier semestriel 2020 auprès de l’Autorité des marchés financiers (« AMF ») le 7 septembre 2020.Il peut être consulté ou téléchargé sur le site internet de la Société www.klepierre.com, rubrique « Espace Finance ».

ADLPartnerSociété anonyme à directoire et conseil de surveillance au capital de 6 478 836 euros3, avenue de Chartres 60500 – CHANTILLY393 376 801 R.C.S. CompiègneDéclaration des transactions sur actions propres réalisées du 31 août au 4 septembre 2020Présentation agrégée par jour et par marchéDétail transaction par transactionRelations Investisseurs & Informations financièresTel : +33 1 41 58 72 03 – Courriel : relations.investisseurs@adlpartner.frADLPartner est cotée sur Euronext Paris – Compartiment CCodes ISIN : FR0000062978-ALP – Bloomberg : ALP FP – Reuters : ALDP.PAwww.adlpartner.comPièce jointeADLPartner_rachats_actions_07092020

WISeKey Semiconductors gets renewal compliance with the international ISO 27001 certification for information securityThe ISO 27001 standard has rigorous requirements for establishing, implementing, maintaining and continually improving a company’s Information Security Management System (ISMS)WISeKey renews its ISO 27001 Certification and WebTrust accreditation, demonstrating its commitment to comply with the most exigent security standards and best practices in the industryGeneva, Switzerland- September 7, 2020- WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, announced today that it has renewed successfully two important security accreditations: (1) the annual independent audit which grants the reputed WebTrust accreditation, necessary to deliver reliable trust...